Suppressor of Cancer Cell Invasion (SCAI) is a multifunctional protein that plays a crucial role in regulating cell migration and invasion, key processes involved in cancer metastasis and tissue remodeling. SCAI exerts its effects by interacting with various components of the cell migration machinery, including actin cytoskeleton dynamics and cell adhesion complexes. By modulating the activity and localization of these components, SCAI can suppress the invasive behavior of cancer cells, making its activation a point of interest for understanding and controlling cancer progression. The protein's function is not limited to cancer cells; it also plays roles in normal cellular processes, such as wound healing and development, where controlled cell movement is essential. The biological significance of SCAI, therefore, extends across both physiological and pathological contexts, underscoring the importance of elucidating the mechanisms that regulate its activity.
The activation of SCAI, or the enhancement of its function, can occur through various biochemical pathways that influence its expression levels, post-translational modifications, or interactions with other proteins. For instance, the transcriptional upregulation of SCAI in response to specific cellular signals or environmental cues can increase its availability to participate in suppressing cell invasion. Post-translational modifications, such as phosphorylation or ubiquitination, may alter SCAI's conformation, localization, or interaction with partner proteins, thereby modulating its activity. Moreover, the binding of SCAI to specific partners can activate its function by targeting it to particular cellular compartments or molecular complexes where it can exert its inhibitory effects on cell migration and invasion. Understanding these mechanisms is crucial for comprehending how SCAI activity is regulated within the cell and how its dysregulation may contribute to disease processes, including cancer metastasis. Insights into the activation of SCAI offer avenues for research into novel strategies for cancer prevention research, emphasizing the broader implications of these regulatory mechanisms in disease biology.
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
An inhibitor of Rho-associated protein kinase (ROCK). May indirectly affect SCAI through the modulation of cytoskeletal dynamics. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Another MEK inhibitor that could potentially modulate cellular processes involving SCAI. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor. JNK pathways, being related to stress and inflammation, can potentially have an influence on SCAI. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $94.00 $286.00 | 27 | |
An inhibitor of Wnt production. Given the role of Wnt signaling in cellular migration and differentiation, it could have an influence on SCAI. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $99.00 $335.00 $836.00 $2099.00 | 47 | |
A gamma-secretase inhibitor, influencing Notch signaling, which might indirectly impact SCAI-associated processes. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $179.00 $307.00 $455.00 $924.00 $1689.00 | 7 | |
An inhibitor of myosin II, affecting cytoskeletal dynamics and potentially SCAI-related pathways. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
A Rac1 inhibitor, playing a role in the modulation of cell morphology and migration, could influence SCAI indirectly. |